Deliver Your News to the World

Emerging Competitors Vie for Burgeoning US Facial Aesthetics Market


September 29, 2005—The stigma that once accompanied facial aesthetic enhancement is now a thing of the past. According to a new report by Millennium Research Group (MRG), in 2005, a growing number of Americans will opt for elective nonsurgical treatments, generating revenues exceeding $430 million in the process. Wider social acceptance, combined with strong industry-backed marketing campaigns, will drive facial aesthetic procedures volumes and product revenues over the next 5 years, enabling the US market to exceed $1 billion by 2010.

Botulinum toxin (BTX) injections, which freeze muscles around the forehead that cause wrinkles, continue to be the most popular facial aesthetic procedure in the US. Dominated by Allergan’s (AGN) Botox Cosmetic product, this market will produce almost $250 million in revenue in 2005. For patients with existing wrinkles and lines, hyaluronic acid (HA) remains the number one choice for wrinkle reduction, with Medicis’ (MRX) Restylane brand leading US sales. Despite the established roles of BTX and HA, demand for longer-lasting particle filler injectables is growing rapidly. While both Bioform Medical and Dermik Labs’ fillers are not yet approved for aesthetic use, sales are expected to increase at an annual rate of almost 20% over the next 5 years.

The use of Collagen, the oldest injectable technology, has declined over the last 2 years due to its limited period of efficacy and the inconvenience of the allergy test required prior to use. The introduction of longer-lasting, non-animal, hypoallergenic, collagen-type injectables from Isolagen (ILE) and Fibrogen should reverse this downward trend. As superior alternatives to existing collagen technologies, the new products promise to substantially expand the US market.

MRG’s US Markets for Facial Aesthetics 2006 includes analyses of the BTX, HA, particle filler, and collagen markets and covers established and emerging competitors, including Anika Therapeutics (ANIK), Artes Medical, Inamed (IMDC), Sanofi-Aventis (SNY) subsidiary Dermik Labs, Fascia Biosystems, Mentor (MNT), Johnson & Johnson (JNJ) subsidiary Ortho-Neutrogena, and Prollennium.

A leading source of competitive intelligence, MRG is now the largest provider of medical device market research in the world. Located in Toronto, Canada, MRG covers global markets and has pioneered reporting of numerous emerging products.


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.